Redhill Biopharma
RDHL
16 hedge funds and large institutions have $1.2M invested in Redhill Biopharma in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 23 closing their positions.
1,118% more call options, than puts
Call options by funds: $134K | Put options by funds: $11K
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
20% less capital invested
Capital invested by funds: $1.51M → $1.2M (-$308K)
57% less funds holding
Funds holding: 37 → 16 (-21)
91% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.96M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$48.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$12.5K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$6.23K |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
+$2.27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.05M |
| 2 |
Morgan Stanley
New York
|
-$80.8K |
| 3 |
Millennium Management
New York
|
-$74K |
| 4 |
Renaissance Technologies
New York
|
-$49K |
| 5 |
GS
Gagnon Securities
New York
|
-$46.6K |
RDHL Hedge Fund Activity: Q1 2023 in Review
16 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q1 2023, worth a combined $1.2M — down 20% from $1.51M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of RDHL and 2 opened new positions — a net loss of 21 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.96M. The largest seller was Sabby Management, exiting entirely with an estimated $1.05M sold.
- 16 institutional investors held Redhill Biopharma (RDHL) as of Q1 2023, down from 37 in Q4 2022.
- Funds reported $1.2M of Redhill Biopharma stock for Q1 2023, down 20% quarter-over-quarter.
- 2 funds opened new Redhill Biopharma positions in Q1 2023 and 23 closed out, a net change of -21 holders.
- The largest Redhill Biopharma buyer in Q1 2023 was Armistice Capital, an estimated $1.96M added.
- The largest Redhill Biopharma seller in Q1 2023 was Sabby Management, an estimated $1.05M sold.
Based on aggregated 13F filings for Q1 2023.